<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693041</url>
  </required_header>
  <id_info>
    <org_study_id>Dnr. 929-11</org_study_id>
    <nct_id>NCT02693041</nct_id>
  </id_info>
  <brief_title>Pregnancy Complications - A Probiotic Interventional Study</brief_title>
  <official_title>Pregnancy Complications - A Probiotic Interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators hypothesize that

        1. intake of milk products containing probiotics are associated with a reduced risk of
           spontaneous preterm delivery.

        2. intake of milk products containing probiotics are associated with a reduced risk of
           preeclampsia.

        3. probiotics decrease the overall inflammatory state in the pregnant woman.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main of the Project is to determine if dietary supplementation intake of probiotics are
      associated with a decreased risk of spontaneous preterm delivery and preeclampsia in a
      randomized Clinical trial. Investigators also want to further investigate the relationship
      between intake of probiotics and the degree of inflammation in different compartments during
      pregnancy to see how the probiotic components affect the inflammatory state in the women.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of women who deliver before 37.0 weeks in the group treated with Lactobacillus rhamnosus and number of women who deliver before 37.0 weeks in the placebo group.</measure>
    <time_frame>during gestation (from week 8 until delivery)</time_frame>
    <description>To evaluate if Lactobacillus rhamnosus reduce the incidence of preterm birth in women with a prior history of preterm birth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of women who develop preeclampsia in the group treated with Lactobacillus rhamnosus and number of women who develop preeclampsia in the placebo group</measure>
    <time_frame>during gestation (from week 8 until delivery)</time_frame>
    <description>To evaluate if Lactobacillus rhamnosus reduce the incidence of preeclampsia in women with a prior history of preeclampsia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of Toll-like receptors after stimulation with Lactobacillus plantarum, Pseudomonas aeruginosa and LPS in women treated with Lactobacillus rhamnosus and in the placebo group (low-risk women)</measure>
    <time_frame>at recruitment, week 25, week 35 of gestation</time_frame>
    <description>In low-risk women, to evaluate the effect on Toll-like receptors levels previously stimuled with Lactobacillus plantarum, Pseudomonas aeruginosa and LPS of Lactobacillus rhamnosus treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Toll-like receptors after stimulation with Lactobacillus plantarum, Pseudomonas aeruginosa and LPS in women treated with Lactobacillus rhamnosus and in the placebo group (prior history of preterm birth)</measure>
    <time_frame>at recruitment, week 25, week 35 of gestation</time_frame>
    <description>In women with a prior preterm birth, to evaluate the effect on Toll-like receptors levels previously stimuled with Lactobacillus plantarum, Pseudomonas aeruginosa and LPS of Lactobacillus rhamnosus treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Toll-like receptors after stimulation with Lactobacillus plantarum, Pseudomonas aeruginosa and LPS in women treated with Lactobacillus rhamnosus and in the placebo group (prior history of preeclampsia)</measure>
    <time_frame>at recruitment, week 25, week 35 of gestation</time_frame>
    <description>In women with a prior history of preeclampsia, to evaluate the effect on Toll-like receptors levels previously stimuled with Lactobacillus plantarum, Pseudomonas aeruginosa and LPS of Lactobacillus rhamnosus treatment</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Preeclampsia</condition>
  <condition>Preterm Birth</condition>
  <arm_group>
    <arm_group_label>PROBIOTIC in low-risk women</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In low-risk women, probiotic group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (&gt; 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO in low-risk women</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In low-risk women, placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROBIOTIC in women with a prior PTB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In women with a prior preterm birth (PTB), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (&gt; 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO in women with a prior PTB</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In women with a prior preterm birth (PTB), placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROBIOTIC in women with a prior PE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In women with a prior preeclampsia (PE), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (&gt; 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO in women with a prior PE</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In women with a prior preeclampsia (PE), placebo Group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>probiotic</intervention_name>
    <description>Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.</description>
    <arm_group_label>PROBIOTIC in low-risk women</arm_group_label>
    <arm_group_label>PROBIOTIC in women with a prior PTB</arm_group_label>
    <arm_group_label>PROBIOTIC in women with a prior PE</arm_group_label>
    <other_name>Lactobacillus rhamnosus</other_name>
    <other_name>LGG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.</description>
    <arm_group_label>PLACEBO in low-risk women</arm_group_label>
    <arm_group_label>PLACEBO in women with a prior PTB</arm_group_label>
    <arm_group_label>PLACEBO in women with a prior PE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Maternal age &gt; or = 18 y

          -  Singleton pregnancy

          -  Nulli or multiparous without maternal intercurrent diseases or pregnant women with a
             history of spontaneous preterm delivery or pregnant women with a history of
             preeclampsia.

        Exclusion Criteria

          -  Multiple pregnancy

          -  Gestational age &gt; 17+6 weeks at first visit

          -  Chronic intermittent diseases (e.g. diabetes mellitus, systemic lupus erythematosus,
             rheumatoid arthritis, Chron disease, ulcerative colitis)

          -  Uterus malformations

          -  Immunomodulatory medication

          -  Hormonal treatment (e.g. crinone, progesterone)

          -  Subject disagrees to stop intake of other products containing probiotics during study
             time.

          -  Subject is unable to provide written informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Jacobsson, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Göteborg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Jacobsson, Professor</last_name>
    <phone>+46313436719</phone>
    <email>bo.jacobsson@obgyn.gu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Hallingstrom, midwife</last_name>
    <phone>+46 31 343 67 31</phone>
    <email>maria.hallingstrom@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bo Jacobsson</name>
      <address>
        <city>Gothenburg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Jacobsson, Professor</last_name>
      <phone>+46313436719</phone>
      <email>bo.jacobsson@obgyn.gu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. The placenta harbors a unique microbiome. Sci Transl Med. 2014 May 21;6(237):237ra65. doi: 10.1126/scitranslmed.3008599.</citation>
    <PMID>24848255</PMID>
  </results_reference>
  <results_reference>
    <citation>Cobo T, Kacerovsky M, Palacio M, Hornychova H, Hougaard DM, Skogstrand K, Jacobsson B. Intra-amniotic inflammatory response in subgroups of women with preterm prelabor rupture of the membranes. PLoS One. 2012;7(8):e43677. doi: 10.1371/journal.pone.0043677. Epub 2012 Aug 20.</citation>
    <PMID>22916296</PMID>
  </results_reference>
  <results_reference>
    <citation>Gonçalves LF, Chaiworapongsa T, Romero R. Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev. 2002;8(1):3-13. Review.</citation>
    <PMID>11921380</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiménez E, Fernández L, Marín ML, Martín R, Odriozola JM, Nueno-Palop C, Narbad A, Olivares M, Xaus J, Rodríguez JM. Isolation of commensal bacteria from umbilical cord blood of healthy neonates born by cesarean section. Curr Microbiol. 2005 Oct;51(4):270-4. Epub 2005 Sep 20.</citation>
    <PMID>16187156</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiménez E, Marín ML, Martín R, Odriozola JM, Olivares M, Xaus J, Fernández L, Rodríguez JM. Is meconium from healthy newborns actually sterile? Res Microbiol. 2008 Apr;159(3):187-93. doi: 10.1016/j.resmic.2007.12.007. Epub 2008 Jan 11.</citation>
    <PMID>18281199</PMID>
  </results_reference>
  <results_reference>
    <citation>Myhre R, Brantsæter AL, Myking S, Gjessing HK, Sengpiel V, Meltzer HM, Haugen M, Jacobsson B. Intake of probiotic food and risk of spontaneous preterm delivery. Am J Clin Nutr. 2011 Jan;93(1):151-7. doi: 10.3945/ajcn.110.004085. Epub 2010 Oct 27.</citation>
    <PMID>20980489</PMID>
  </results_reference>
  <results_reference>
    <citation>Brantsaeter AL, Myhre R, Haugen M, Myking S, Sengpiel V, Magnus P, Jacobsson B, Meltzer HM. Intake of probiotic food and risk of preeclampsia in primiparous women: the Norwegian Mother and Child Cohort Study. Am J Epidemiol. 2011 Oct 1;174(7):807-15. doi: 10.1093/aje/kwr168. Epub 2011 Aug 5.</citation>
    <PMID>21821542</PMID>
  </results_reference>
  <results_reference>
    <citation>Bertelsen RJ, Brantsæter AL, Magnus MC, Haugen M, Myhre R, Jacobsson B, Longnecker MP, Meltzer HM, London SJ. Probiotic milk consumption in pregnancy and infancy and subsequent childhood allergic diseases. J Allergy Clin Immunol. 2014 Jan;133(1):165-71.e1-8. doi: 10.1016/j.jaci.2013.07.032. Epub 2013 Sep 10.</citation>
    <PMID>24034345</PMID>
  </results_reference>
  <results_reference>
    <citation>Yeganegi M, Watson CS, Martins A, Kim SO, Reid G, Challis JR, Bocking AD. Effect of Lactobacillus rhamnosus GR-1 supernatant and fetal sex on lipopolysaccharide-induced cytokine and prostaglandin-regulating enzymes in human placental trophoblast cells: implications for treatment of bacterial vaginosis and prevention of preterm labor. Am J Obstet Gynecol. 2009 May;200(5):532.e1-8. doi: 10.1016/j.ajog.2008.12.032. Epub 2009 Mar 14.</citation>
    <PMID>19285652</PMID>
  </results_reference>
  <results_reference>
    <citation>Yeganegi M, Leung CG, Martins A, Kim SO, Reid G, Challis JR, Bocking AD. Lactobacillus rhamnosus GR-1 stimulates colony-stimulating factor 3 (granulocyte) (CSF3) output in placental trophoblast cells in a fetal sex-dependent manner. Biol Reprod. 2011 Jan;84(1):18-25. doi: 10.1095/biolreprod.110.085167. Epub 2010 Sep 1.</citation>
    <PMID>20811016</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Bo Jacobsson</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>inflammation</keyword>
  <keyword>immunological response</keyword>
  <keyword>preterm birth</keyword>
  <keyword>preeclampsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

